目的 探讨艾愈胶囊联合顺铂注射液治疗卵巢癌的临床疗效。方法 选取2016年6月—2018年6月延安大学附属医院接收的100例卵巢癌患者为研究对象，将所有患者随机分为对照组和治疗组，每组各50例。对照组患者静脉滴注顺铂注射液80 mg/m²，1次/4周；治疗组在对照组治疗的基础上口服艾愈胶囊，3粒/次，3次/d。4周为1个疗程，两组患者连续治疗3个疗程。观察两组的临床疗效，比较两组的卡式功能状态（KPS）评分、生活质量（QDL）评分、血清肿瘤标志物水平。结果 治疗后，对照组和治疗组的临床有效率（ORR）分别为56.00%、72.5%，疾病控制率（CBR）分别为78.00%、84.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者KPS评分、QDL评分均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组KPS评分、QDL评分明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者血清癌胚抗原（CEA）、糖蛋白199（CA199）、糖蛋白125（CA125）和糖蛋白153（CA153）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组血清肿瘤标志物水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 艾愈胶囊联合顺铂注射液治疗卵巢癌具有较好的疗效，能改善患者生活质量，降低肿瘤标志物水平，安全性较高，具有一定的临床推广应用价值。

Objective To investigate the efficacy of Aiyu Capsules combined with Cisplatin Injection in treatment of ovarian cancer. Methods Patients (100 cases) with ovarian cancer in Yan'an University Affiliated Hospital from June 2016 to June 2018 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were iv administered with Cisplatin Injection 80 mg/m², once every four weeks. Patients in the treatment group were po administered with Aiyu Capsules on the basis of the control group, 3 grains/time, three times daily. A course of treatment had four weeks, and patients in two groups were treated for 3 courses. After treatment, the clinical efficacies were evaluated, and KPS scores, QDL scores, and serum levels of tumor markers in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 56.00% and 72.5%, respectively, and the CBR in the control and treatment groups were 78.00% and 84.00%, respectively, and there was difference between two groups (P<0.05). After treatment, KPS scores and QDL scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CEA, CA199, C125, and CA153 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of tumor markers in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Aiyu Capsules combined with Cisplatin Injection has clinical curative effect in treatment of ovarian cancer, can improve the quality of life of patients, and reduce the level of tumor markers, with good safety, which has a certain application value.